Key approvals and fast-track designations for Insmed, Alto Neuroscience, and Corcept Therapeutics boost investor confidence in the industry's regulatory landscape.
Zepzelca, in combination with Roche's Tecentriq, is the first approved first-line maintenance therapy for extensive-stage small cell lung cancer.
ProSense cryoablation system gains marketing authorization as the first minimally invasive treatment for low-risk tumors in women over 70.
Regulators expedite review for ALTO-101, a novel treatment for cognitive impairment in schizophrenia, a condition with no currently approved therapies.
GM, Ford, and Stellantis shares climb on news of potential tariff exemptions for U.S. vehicles, signaling a policy shift.
Government award will advance the company's non-vaccine influenza therapeutic, CD388, and onshore its manufacturing ahead of a potential pandemic.
The bank projects a near-term price target of $135,000 for Bitcoin, citing heavy ETF inflows and a break from historical post-halving patterns.
Regulators expedite review for ALTO-101, targeting a key aspect of schizophrenia with no currently approved treatments.